Clinical Trials Logo
  1. Home
  2. Avian Influenza
  3. NCT00561184

Safety and Immunogenicity of a Booster Dose of -H5N1 Influenza Vaccine

Avian Influenza Clinical Trial

Official title:
A Phase II, Open-label, Multi-Center Study to Evaluate Safety and Immunogenicity of a Booster Dose of -H5N1 (Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccine in Non-elderly Adult and Elderly Subjects

Clinical Trial Summary

To assess persistence of antibody titers 17-18 months after primary immunization with two 0.5mL intramuscular (IM) doses of H5N1 influenza vaccine containing H5N1 influenza antigen, as measured by Hemagglutination Inhibition (HI), Single Radial Hemolysis (SRH), and Microneutralization (MN) test

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00561184
Study type Interventional
Source Novartis
Contact
Status Completed
Phase Phase 2
Start date October 2007
Completion date June 2008
View Details
See also
  Status Clinical Trial Phase
Completed NCT01698060 - Immunogenicity of ND1.1 by Delivery Directly to the Ileum Phase 1
Completed NCT02213354 - H7N9 Mix and Match With MF59 in Healthy Elderly Persons Phase 2
Completed NCT02295813 - Safety and Pharmacokinetics Study of FBF001 Phase 1
Completed NCT02921997 - H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses Phase 2
Completed NCT03682120 - Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza Phase 2
Completed NCT00895544 - Immunogenicity and Safety Study of a Single Prime-Boost Vaccination Schedule With a H5N1 Influenza Vaccine in Adults Phase 1/Phase 2
Completed NCT02251288 - A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine Phase 1
Completed NCT02612909 - A Safety and Immunogenicity Study of IVACFLU-A/H5N1 Phase 2/Phase 3
Completed NCT02229357 - Evaluation of Priming Effects by PLAI Vaccine on the Subsequent Response to Inactivated H5N1 Vaccine Phase 2
Completed NCT01150552 - Studies of Avian Influenza Transmission to Humans in Egypt N/A
Completed NCT03472976 - H5N1 With or Without Topical Aldara in Healthy Adults Phase 1
Completed NCT01897701 - A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1 Phase 1
Completed NCT01107262 - Avian Influenza Studies In Lebanon N/A
Completed NCT02839330 - A Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age Phase 3
Completed NCT03014310 - H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology Phase 1
Completed NCT00298233 - High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza Phase 2
Completed NCT03318315 - Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4 Phase 2
Completed NCT03312231 - Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly Phase 2
Completed NCT03738241 - 2017 A/H7N9 IIV Revaccination Phase 2
Completed NCT03589807 - 2013/2017 H7N9 Prime-Boost Interval Phase 2